GB-263

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameGB-263

Drug Alias NameGB-263GB-263T

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionHepatocyte growth factor receptor inhibitorsEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustraliaMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesGenor Biopharma Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGenor Biopharma Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A